<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022113</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02392</org_study_id>
    <secondary_id>00-1096</secondary_id>
    <secondary_id>U01CA099176</secondary_id>
    <secondary_id>CDR0000068786</secondary_id>
    <nct_id>NCT00022113</nct_id>
  </id_info>
  <brief_title>EMD 121974 in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of EMD 121974 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of EMD 121974 in treating patients who have advanced&#xD;
      solid tumors. EMD 121974 may slow the growth of solid tumors by stopping blood flow to the&#xD;
      tumor&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxic effects and maximum tolerated dose of EMD 121974 in patients with&#xD;
      advanced solid tumors.&#xD;
&#xD;
      II. Determine the biologic activity of this drug in these patients. III. Determine the&#xD;
      pharmacokinetic profile and plasma biological effects of this drug and identify any&#xD;
      relationship with its biologic activity or observed toxicity in these patients.&#xD;
&#xD;
      IV. Determine, preliminarily, the antitumor efficacy of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-10 patients receive escalating doses of EMD 121974 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of cilengitide defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Graded according to the NCI Common Toxicity Criteria version 2.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxic effects of cilengitide described as an adverse event that has an attribution of possibly, probably or definitely related to investigational treatment</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Graded according to the NCI Common Toxicity Criteria version 2.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological activity of this regimen</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Measured buy TUNEL assay, CD31 immunohistochemistry, dynamic contrast-enhanced MRI, and FDG-PET scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of cilengitide</measure>
    <time_frame>At 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 8.0, and 24.0 hours post-end-of-infusion on day 1 of course 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observation of response consisting of complete response, partial response, or stable disease, evaluated using the RECIST criteria</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (cilengitide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilengitide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (cilengitide)</arm_group_label>
    <other_name>EMD 121974</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cilengitide)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cilengitide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor that is refractory to standard therapy or for&#xD;
             which no standard therapy exists&#xD;
&#xD;
          -  Tumors must be amenable to minimally-invasive biopsy (i.e., tumors must be superficial&#xD;
             enough to be sampled by punch biopsy or core biopsy procedure without radiologic&#xD;
             guidance)*&#xD;
&#xD;
          -  No uncontrolled brain metastases, including symptomatic lesions or lesions requiring&#xD;
             glucocorticoids and/or anticonvulsants to suppress symptoms&#xD;
&#xD;
               -  Negative brain scan required if there are signs and symptoms suggestive of brain&#xD;
                  metastasis&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other concurrent serious systemic disorders (e.g., significant CNS illness) that&#xD;
             would preclude study&#xD;
&#xD;
          -  No concurrent psychiatric illness or social situations that would preclude study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent anticancer immunotherapy&#xD;
&#xD;
          -  Concurrent hematologic growth factors for cytopenias allowed&#xD;
&#xD;
          -  At least 4 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas,&#xD;
             carmustine, or mitomycin) and recovered&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
          -  Concurrent oral contraceptives or postmenopausal hormone replacement allowed&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior palliative radiotherapy to bone or brain metastases&#xD;
&#xD;
          -  At least 4 weeks since prior anticancer radiotherapy&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
          -  At least 4 weeks since prior anticancer therapy and recovered&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  Any number of prior therapies allowed&#xD;
&#xD;
          -  No other concurrent anticancer investigational or commercial agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Basche</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

